Selected research
Industry Research
Gastric Carcinomas Drugs Industry Research Report 2026
Market perspective
The global Gastric Carcinomas Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Gastric Carcinomas Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Gastric Carcinomas Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Gastric Carcinomas Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Gastric Carcinomas Drugs include Chiatai Tianqing, Fujian Haiwang Fuyao Pharmacy Limited Company, Merck & Co, Novo Nordisk, Taiho Pharmaceutical, Bayer, Jiangsu Hengrui Medicine Company Limited, Pfizer and Eli Lilly and Company, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Gastric Carcinomas Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Gastric Carcinomas Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gastric Carcinomas Drugs Market by Company
Chiatai Tianqing
Fujian Haiwang Fuyao Pharmacy Limited Company
Merck & Co
Novo Nordisk
Taiho Pharmaceutical
Bayer
Jiangsu Hengrui Medicine Company Limited
Pfizer
Eli Lilly and Company
Roche
Qilu Pharma
Shandong New Era Hotel Pharmaceutical Industry Limited Company
Gastric Carcinomas Drugs Segment by Type
First Line Treatment
Second Line Treatment
Three Line Treatment
Gastric Carcinomas Drugs Segment by Application
Hospital
Clinic
Others
Gastric Carcinomas Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Carcinomas Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Carcinomas Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Carcinomas Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Gastric Carcinomas Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- First Line Treatment
- Second Line Treatment
- Three Line Treatment
Applications
- Hospital
- Clinic
- Others
Companies covered
- Chiatai Tianqing
- Fujian Haiwang Fuyao Pharmacy Limited Company
- Merck & Co
- Novo Nordisk
- Taiho Pharmaceutical
- Bayer
- Jiangsu Hengrui Medicine Company Limited
- Pfizer
- Eli Lilly and Company
- Roche
- Qilu Pharma
- Shandong New Era Hotel Pharmaceutical Industry Limited Company
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gastric Carcinomas Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 First Line Treatment
- 2.2.3 Second Line Treatment
- 2.2.4 Three Line Treatment
- 2.3 Gastric Carcinomas Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Gastric Carcinomas Drugs Breakdown Data by Type
- 3.1 Global Gastric Carcinomas Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Type (2027-2032)
4 Gastric Carcinomas Drugs Breakdown Data by Application
- 4.1 Global Gastric Carcinomas Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Gastric Carcinomas Drugs Market Perspective (2021-2032)
- 5.2 Global Gastric Carcinomas Drugs Growth Trends by Region
- 5.2.1 Global Gastric Carcinomas Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Gastric Carcinomas Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Gastric Carcinomas Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Gastric Carcinomas Drugs Market Dynamics
- 5.3.1 Gastric Carcinomas Drugs Industry Trends
- 5.3.2 Gastric Carcinomas Drugs Market Drivers
- 5.3.3 Gastric Carcinomas Drugs Market Challenges
- 5.3.4 Gastric Carcinomas Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Gastric Carcinomas Drugs Players by Revenue
- 6.1.1 Global Top Gastric Carcinomas Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Gastric Carcinomas Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Gastric Carcinomas Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Gastric Carcinomas Drugs Head Office and Area Served
- 6.4 Global Gastric Carcinomas Drugs Players, Product Type & Application
- 6.5 Global Gastric Carcinomas Drugs Manufacturers Established Date
- 6.6 Global Gastric Carcinomas Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Gastric Carcinomas Drugs Market Size (2021-2032)
- 7.2 North America Gastric Carcinomas Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 7.4 North America Gastric Carcinomas Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Gastric Carcinomas Drugs Market Size (2021-2032)
- 8.2 Europe Gastric Carcinomas Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 8.4 Europe Gastric Carcinomas Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Gastric Carcinomas Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Gastric Carcinomas Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Gastric Carcinomas Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Gastric Carcinomas Drugs Market Size (2021-2032)
- 10.2 South America Gastric Carcinomas Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 10.4 South America Gastric Carcinomas Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Gastric Carcinomas Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Gastric Carcinomas Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Chiatai Tianqing
- 12.1.1 Chiatai Tianqing Company Information
- 12.1.2 Chiatai Tianqing Business Overview
- 12.1.3 Chiatai Tianqing Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.1.4 Chiatai Tianqing Gastric Carcinomas Drugs Product Portfolio
- 12.1.5 Chiatai Tianqing Recent Developments
- 12.2 Fujian Haiwang Fuyao Pharmacy Limited Company
- 12.2.1 Fujian Haiwang Fuyao Pharmacy Limited Company Company Information
- 12.2.2 Fujian Haiwang Fuyao Pharmacy Limited Company Business Overview
- 12.2.3 Fujian Haiwang Fuyao Pharmacy Limited Company Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.2.4 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Product Portfolio
- 12.2.5 Fujian Haiwang Fuyao Pharmacy Limited Company Recent Developments
- 12.3 Merck & Co
- 12.3.1 Merck & Co Company Information
- 12.3.2 Merck & Co Business Overview
- 12.3.3 Merck & Co Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.3.4 Merck & Co Gastric Carcinomas Drugs Product Portfolio
- 12.3.5 Merck & Co Recent Developments
- 12.4 Novo Nordisk
- 12.4.1 Novo Nordisk Company Information
- 12.4.2 Novo Nordisk Business Overview
- 12.4.3 Novo Nordisk Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.4.4 Novo Nordisk Gastric Carcinomas Drugs Product Portfolio
- 12.4.5 Novo Nordisk Recent Developments
- 12.5 Taiho Pharmaceutical
- 12.5.1 Taiho Pharmaceutical Company Information
- 12.5.2 Taiho Pharmaceutical Business Overview
- 12.5.3 Taiho Pharmaceutical Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.5.4 Taiho Pharmaceutical Gastric Carcinomas Drugs Product Portfolio
- 12.5.5 Taiho Pharmaceutical Recent Developments
- 12.6 Bayer
- 12.6.1 Bayer Company Information
- 12.6.2 Bayer Business Overview
- 12.6.3 Bayer Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.6.4 Bayer Gastric Carcinomas Drugs Product Portfolio
- 12.6.5 Bayer Recent Developments
- 12.7 Jiangsu Hengrui Medicine Company Limited
- 12.7.1 Jiangsu Hengrui Medicine Company Limited Company Information
- 12.7.2 Jiangsu Hengrui Medicine Company Limited Business Overview
- 12.7.3 Jiangsu Hengrui Medicine Company Limited Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.7.4 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Product Portfolio
- 12.7.5 Jiangsu Hengrui Medicine Company Limited Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.8.4 Pfizer Gastric Carcinomas Drugs Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 Eli Lilly and Company
- 12.9.1 Eli Lilly and Company Company Information
- 12.9.2 Eli Lilly and Company Business Overview
- 12.9.3 Eli Lilly and Company Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.9.4 Eli Lilly and Company Gastric Carcinomas Drugs Product Portfolio
- 12.9.5 Eli Lilly and Company Recent Developments
- 12.10 Roche
- 12.10.1 Roche Company Information
- 12.10.2 Roche Business Overview
- 12.10.3 Roche Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.10.4 Roche Gastric Carcinomas Drugs Product Portfolio
- 12.10.5 Roche Recent Developments
- 12.11 Qilu Pharma
- 12.11.1 Qilu Pharma Company Information
- 12.11.2 Qilu Pharma Business Overview
- 12.11.3 Qilu Pharma Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.11.4 Qilu Pharma Gastric Carcinomas Drugs Product Portfolio
- 12.11.5 Qilu Pharma Recent Developments
- 12.12 Shandong New Era Hotel Pharmaceutical Industry Limited Company
- 12.12.1 Shandong New Era Hotel Pharmaceutical Industry Limited Company Company Information
- 12.12.2 Shandong New Era Hotel Pharmaceutical Industry Limited Company Business Overview
- 12.12.3 Shandong New Era Hotel Pharmaceutical Industry Limited Company Revenue in Gastric Carcinomas Drugs Business (2021-2026)
- 12.12.4 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Product Portfolio
- 12.12.5 Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst